ãã®èšäºãèªãããšã§åããã¡ãªãããšçµè«
çµè«ïŒèŠçŽïŒïŒå€ãã®ã±ãŒã¹ã§å»çè±æ¯ã®çã¿å¯ŸçãšããŠãããœãã³ïŒNSAIDsïŒã¯æå¹ã«äœ¿ãããŠããŸãããæç
ãåžžçšè¬ãåŠåš ã»æä¹³ãªã©ã®æ¡ä»¶ã«ãã£ãŠã¯é¿ããã»ããããå ŽåããããŸããæœè¡ååŸã®æçšã¿ã€ãã³ã°ã1åéã代æ¿è¬ïŒã«ãããŒã«ïŒã¢ã»ãã¢ãããã§ã³ïŒãéè¬ç©çã±ã¢ïŒå·åŽã麻é
ã¯ãªãŒã ãç¬æ°éº»é
ïŒã®éžã³æ¹ãŸã§ãã¯ãªããã¯ããšã®å¯Ÿå¿ãèžãŸããŠå®å
šã«å¯ŸåŠããæ¹æ³ãããããŸãã
ãã®èšäºãèªããšïŒ
- ãããœãã³ïŒåžè²©ã®ãããœãã³Så«ãïŒãå»çè±æ¯ã®çã¿ã«ã©ãå¹ããçè§£ã§ãã
- ãã€é£²ãã¹ãããã©ãããã飲ãã°ãããã®äžè¬çãªç®å®ãåããïŒæçµå€æã¯å»åž«ãåªå
ïŒ
- åºè¡ãªã¹ã¯ãå¯äœçšãè¬ã®é£²ã¿åããã®æ³šæç¹ãããã
- æ¹åçŸå®¹ã¯ãªããã¯ãã¬ãžãŒãã¯ãªããã¯ããªãŒã¯ãªããã¯ãªã©ã®äžè¬çãªå¯Ÿå¿ãå£ã³ãåŸåãææ¡ã§ãã
- è¬ä»¥å€ã®é®çæ³ïŒå·ããã麻é
ã¯ãªãŒã ãç¬æ°ãªã©ïŒã«ã€ããŠå®è·µçã«éžã¹ã
1. ãããœãã³ãšã¯ïŒå»çè±æ¯ã®çã¿ãšã©ãé¢ä¿ããã®ã â åºç€ããããããçè§£ããã
å»çè±æ¯ã®çã¿ãæããããšãããŸãã¯ããããœãã³ã£ãŠããããäœïŒããæŒãããŸããããçã¿ã®ä»çµã¿ãšè¬ã®äœçšããããã°ããã€äœ¿ãã¹ãã倿ãããããªããŸãã
1-1. ãããœãã³ïŒãããœãã³Sã£ãŠäœïŒæåãšäœçšãã·ã³ãã«ã«èª¬æ
ãããœãã³ã¯æååãããœãããã§ã³ïŒNSAIDsïŒéã¹ããã€ãæ§æççè¬ïŒãå«ãè¬ã®ãã©ã³ãåã§ãåŠæ¹è¬ãšããŠã®ããããœãã³é ããåžè²©ã®ããããœãã³SãããããŸããççãåŒãèµ·ããããã¹ã¿ã°ã©ã³ãžã³ã®çæãæããçã¿ãçºç±ãççãåãããŸãã
1-2. NSAIDsã®ããã¿ïŒççã»çã¿ãæããä»çµã¿ïŒ
NSAIDsã¯ã·ã¯ããªãã·ã²ããŒãŒïŒCOXïŒãšããé
µçŽ ã®åããæããŠããã¹ã¿ã°ã©ã³ãžã³ç£çãæžãããç¥çµã®çã¿ã·ã°ãã«ãççãæããŸããå¹æã¯æ¯èŒçéããé®çã»æççäœçšãæåŸ
ã§ããŸãããèè
žãè
èãžã®åœ±é¿ãåºè¡ãªã¹ã¯ã®å¢å ãšãã£ãå¯äœçšã«æ³šæãå¿
èŠã§ãã
1-3. å»çè±æ¯ã§æããçã¿ã®æ£äœïŒã¬ãŒã¶ãŒã®ç±ã»ç¥çµãžã®åºæ¿ïŒ
ã¬ãŒã¶ãŒè±æ¯ãç±ãäœ¿ãæ©åšã¯ãæ¯ã®æ¯æ ¹ã«ç±ãã¡ãŒãžãäžããŠæ¯ãæžãããŸãããã®ãšãåšå²ã®ç®èãç¥çµæ«ç«¯ãç±åºæ¿ãåãããã¯ããšããçã¿ãããªããªæãæœè¡åŸã®ãºããºãããçã¿ãåºãŸããéšäœïŒVIOããã²ã¯çã¿ã匷ãïŒãåäººå·®ãæ©åšã«ãã£ãŠçã¿ã®æãæ¹ãå€ãããŸãã
1-4. ãããœãã³ãå¹ããããçã¿ïŒå¹ãã«ããçã¿
ãããœãã³ã¯ççæ§ã®çã¿ïŒæœè¡ã«ããççãç±ã«ããè
«ãïŒã«ã¯æ¯èŒçå¹ããããã§ããäžæ¹ã§ç¬éçãªåºããããªåŒ·ãçã¿ãç¥çµåºæ¿ãäž»äœã®çã¿ã¯ãNSAIDsã ãã§ã¯ååã§ãªãããšããããŸããããããå Žåã¯å±æéº»é
ãç¬æ°ã®äœµçšãå·åŽã§ã®ç·©åãå¿
èŠã§ãã
1-5. åžè²©ïŒãããœãã³SïŒãšåŠæ¹ãããœãã³ã®éãïŒçšéã»é
åã®éãïŒ
åžè²©ã®ãããœãã³Sã¯1å60mgãªã©ã®æ¯èŒçå°éã§è²©å£²ãããããšãå€ããèé
žã«ããè² æ
ãå°ãªããã工倫ãããã補å€ããããŸããåŠæ¹è¬ã®ãããœãã³é ã¯å»åž«ã®å€æã§çšéïŒå»çæ©é¢ã§ã¯äžè¬ã«60ïœ120mg/åïŒãåæ°ã調æŽããŸããåžè²©è¬ã¯èªå·±å€æã§äœ¿ããããåé¢ãæç
ãä»è¬ãšã®çžäºäœçšãèŠèœãšãå±éºãããããæ³šæãå¿
èŠã§ãã
2. ããã€ããã©ã®ãããã飲ãã°ããïŒãããœãã³ã®æçšã¿ã€ãã³ã°ãšç®å®
ã飲ãã¹ãããããã€é£²ãããã¯ããããçåãããã§ã¯äžè¬çãªã¬ã€ãã©ã€ã³ãšã¯ãªããã¯ã§ã®æç€ºäŸããããããã瀺ããŸãã
2-1. æœè¡åã«é£²ãã§ãããïŒïŒäºé²å
æã®ã¡ãªãããšãã¡ãªãã
äºé²çã«æœè¡åã«ãããœãã³ã飲ãããã¬ã¡ãã£ã±ãŒã·ã§ã³ãã¯ãæœè¡çŽåŸã®çã¿ãåããã广ãæåŸ
ã§ããŸããäžæ¹ã§ãNSAIDsã¯åºè¡åŸåãè¥å¹²é«ããå¯èœæ§ããããããã¯ãªããã¯ã«ãã£ãŠã¯äºåæçšãæšå¥šããªãå ŽåããããŸããå¿
ãæœè¡åã«ã¯ãªããã¯ã®æç€ºã確èªããŸãããã
2-2. æœè¡çŽåŸïœæ°æéåŸã®æšå¥šã¿ã€ãã³ã°ïŒçã¿ã®ããŒã¯ãšé£²ãã¿ã€ãã³ã°
ã¬ãŒã¶ãŒè±æ¯åŸã®çã¿ã¯æ°æé以å
ã«ããŒã¯ãè¿ããããšãå€ãã§ããçã¿ãæãããæ©ãã«æçšããããšã§å¹æçã«é®çã§ããŸããæœè¡çŽåŸã«è»œãçã¿ãããå Žåã¯å·åŽãšåæã«å±æå¯ŸåŠããçã¿ã匷ããã°ãããœãã³ã飲ãã®ãäžè¬çã§ãã
2-3. 1åãããã®çšéãšééïŒæäººã®äžè¬çãªç®å®ïŒ
äžè¬çã«ã¯æäººã§ãããœãã³ïŒãããœãããã§ã³ïŒã¯1å60ïœ100mgãå¿
èŠã«å¿ããŠ4ïœ6æéæ¯ã«æçšã1æ¥æå€§çšéã¯èŠå®ã«åŸããŸãããã ãåžè²©è¬ïŒãããœãã³SïŒã¯è£œåã®çšæ³çšéãå®ãããšãæçµå€æã¯å¿
ãå»åž«ãŸãã¯è¬å€åž«ã®æç€ºã«åŸã£ãŠãã ããã
2-4. ç¶ç¶æçšã®ç®å®ãšã飲ã¿ãããã«æ³šæãã¹ãçç¶
è±æ¯ã®çã¿ã§é£æ¥ãããœãã³ã飲ãå¿
èŠãããå Žåãèè
žçç¶ïŒèçãåãæ°ïŒãè¡äŸ¿ãæ¥ãªåŠæ æãå°¿éæžå°ãçºç¹ãªã©ãåºããçŽã¡ã«äžæ¢ãå»åž«ã«çžè«ããŠãã ãããé·æé£çšã®ãªã¹ã¯ãè
æ©èœãžã®åœ±é¿ããããŸãã
2-5. æœè¡åœæ¥ã«é¿ããã»ããè¯ãè¡çºïŒã¢ã«ã³ãŒã«ã匷ãéåãªã©ïŒ
NSAIDsãšã¢ã«ã³ãŒã«ã®äœµçšã¯èè
žãžã®è² æ
ãå¢ããããæ§ããã»ããå®å
šã§ããæœè¡åœæ¥ã¯æ¿ããéåãå
¥æµŽã§ã®é·æéã®æž©ç±ã¯æ§ããå·åŽãå®éãåªå
ããŠãã ããã
3. éšäœå¥ã»æ©åšå¥ã§å€ããçã¿ãšãããœãã³ã®äœ¿ãæ¹ïŒã¯ãã»VIOã»ãã²ãªã©ïŒ
è±æ¯ã®çã¿ã¯éšäœãšæ©åšã§ããªãå€ãããŸããããã§ã¯å
·äœçã«éšäœããšã®ç¹åŸŽãšãããœãã³ã®äœ¿ãæ¹ã玹ä»ããŸãã
3-1. ã¯ãè±æ¯ïŒçã¿åŸåãšå®çšçãªé®çæ³ïŒå·åŽïŒãããœãã³ïŒ
ã¯ãã¯çã¿ã®æãæ¹ãäžçšåºŠïœåŒ·ãã§ãããã¬ãŒã¶ãŒç
§å°åŸããã«å·ããããšã§ããªãç·©åããŸãããããœãã³ã¯ççã匷ããªã£ãå Žåã®é®çã«æå¹ãè€æ°åã®æœè¡ã§çã¿ã¯æ
£ããŠæ¥œã«ãªãã±ãŒã¹ãå€ãã§ãã
3-2. VIOè±æ¯ïŒåŒ·ãçã¿ãžã®å¯ŸåŠæ³ïŒå±æéº»é
ãç¬æ°ããããœãã³ã®äœçœ®ã¥ãïŒ
VIOã¯ç®èãèãç¥çµãå¯ãªããçã¿ã匷ãéšäœã§ããå€ãã®ã¯ãªããã¯ã§ã¯å±æéº»é
ã¯ãªãŒã ãç¬æ°éº»é
ïŒããããªããµã€ãïŒãå Žåã«ãã£ãŠã¯å±ææ³šå°ãªã©ãçšããŸãããããœãã³ã¯è¡åŸã®ççæ§çŒçã«æå¹ã§ãããæœè¡äžã®åŒ·çãªçã¿ã¯éº»é
ç³»ã§å¯Ÿçããã®ãçŸå®çã§ãã
3-3. é¡ïŒãã²ïŒè±æ¯ïŒç®èãèãéšäœã®æ³šæç¹ãšè¬ã®éžã³æ¹
é¡ã¯ç®èãèãèµ€ã¿ãè
«ããç®ç«ã¡ãããã®ã§ãNSAIDsã§ççãæããéžæã¯ãããŸãããèµ€ã¿ãé·åŒãå Žåã¯å€çšã±ã¢ãã¹ããã€ãã®çæäœ¿çšãªã©å»åž«ã®å€æãä»°ããŸããã«ãããŒã«ïŒã¢ã»ãã¢ãããã§ã³ïŒãéžã¶äººãå€ããèã«ããããåºè¡ãªã¹ã¯ãäœãã®ãå©ç¹ã§ãã
3-4. å
šèº«ã»èäžã»èã®è±æ¯ïŒé·æéæœè¡æã®çã¿ç®¡ç
å
šèº«è±æ¯ã¯æœè¡æéãé·ãç²åŽã䌎ããããéšäœããšã«å·åŽãšäŒæ©ãæããå±æéº»é
ã䜵çšãããªã©å·¥å€«ããŸããæœè¡åŸã®å
šäœçãªçèçã®ãããªçã¿ã«ã¯ãããœãã³ãå¹ãããšãå€ãã§ãããäœèª¿ãæç
ã«ããå¶éã確èªããŠãã䜿ããŸãããã
3-5. æ©åšå¥ã®çã¿ã®ç¹åŸŽïŒãžã§ã³ãã«ã¬ãŒãºãã¡ãã£ãªã¹ã¿ãŒããœãã©ãã¢ã€ã¹çïŒ
- ãžã§ã³ãã«ã¬ãŒãºïŒã¢ã¬ããµã³ãã©ã€ãç³»ïŒïŒç¬éçã«åŒ·ãçã¿ãæãããããå·åŽãéèŠã
- ã¡ãã£ãªã¹ã¿ãŒïŒèç±åïŒïŒãããããšæãããæããã¿ã€ãã§çã¿ã¯æ¯èŒçç©ãããé£ç¶ç
§å°ã§èä¹
æ§ãããã
- ãœãã©ãã¢ã€ã¹ïŒèç±æè¡ã§çã¿ãå°ãªãã ããé·æéåœãŠãããç±æãç¶ãããšãããã
æ©åšéžã³ã§çã¿ã®æãæ¹ã¯å€ãããããã¯ãªããã¯ã§çžè«ããŠé©åãªæ©åšãé®çæ³ãéžã³ãŸãããã
4. ãããœãã³ãšå»çè±æ¯ã®å®å
šæ§ã»å¯äœçšïŒçåããã¹ãŠè§£æ¶ïŒ
è¬ã飲ããšãã¯å¹æã ãã§ãªããªã¹ã¯ãç¥ãããšã倧åã§ããããã§ã¯å¯äœçšã泚æç¹ãå
·äœçã«æŽçããŸãã
4-1. ãããœãã³ã®äž»ãªå¯äœçšïŒèè
žçç¶ãè
æ©èœãžã®åœ±é¿ãã¢ã¬ã«ã®ãŒïŒ
NSAIDsã®ä»£è¡šçå¯äœçšã¯èçãæ¶åæ§æœ°çãè
æ©èœäœäžãã¢ã¬ã«ã®ãŒïŒè麻ç¹ã忝ã®èªçºïŒã§ããç¹ã«é«éœ¢è
ãæ
¢æ§è
äžå
šãæ¶åæ§æœ°çã®æ¢åŸãããäººã¯æ³šæãå¿
èŠã§ãã
4-2. åºè¡åŸåïŒNSAIDsã¯åºè¡ãªã¹ã¯ãäžããïŒïŒãšç®èã®æ²»çãžã®åœ±é¿
NSAIDsã¯è¡å°æ¿æ©èœã«åœ±é¿ããããã¿ã€ãã®è¬ãšæ¯ã¹ãã°åºè¡æéãžã®åœ±é¿ã¯éå®çã§ãããåºè¡ãªã¹ã¯ããããã«é«ããããšãå ±åãããŠããŸããæœè¡éšäœã®åºè¡ãããã¶ãã®åœ¢æã«äžå®ããããªããæœè¡åã«å»åž«ã«çžè«ããŸãããã
4-3. èã®èµ€ã¿ã»ççãæªåããªããïŒèšåºçãªèãæ¹ãšå®äŸ
äžè¬çã«ãããœãã³ã¯ççãæããããèµ€ã¿ãè
«ããåããã广ããããŸãããã ãè¬ã§é ããææã®ãµã€ã³ãèŠéããªãããã«ããèµ€ã¿ãã²ã©ãç±æãè¿ãåºããšãã¯å°éå»ã«å蚺ããŠãã ããã
4-4. ä»è¬ãšã®é£²ã¿åããïŒæååºè¬ãéå§è¬ãã¹ããã€ããªã©ïŒãšæ³šæç¹
ã¯ã«ãã¡ãªã³ãªã©ã®æååºè¬ãæçšããŠããå Žåã¯NSAIDsãšã®äœµçšã§åºè¡ãªã¹ã¯ãäžãããããåºæ¬ã¯äž»æ²»å»ã«çžè«ããŠããã«ããŸãããŸãäžéšã®éå§è¬ãå©å°¿è¬ãšãçžäºäœçšã®å¯èœæ§ããããããåžžçšè¬ã¯å¿
ãäºåã«ç³åããŸãããã
4-5. åŠåš äžã»æä¹³äžã»åã©ãã»é«éœ¢è
ã®å Žåã®å¯Ÿå¿ïŒã«ãããŒã«ãªã©ä»£æ¿æ¡ïŒ
åŠåš åŸæã§ã¯NSAIDsã¯èå
埪ç°ãçŸæ°Žã®åœ±é¿ãæžå¿µãããããé¿ããã¹ãã§ããæä¹³äžã¯è£œå€ã«ãã£ãŠã¯äœ¿çšå¯åŠãå€ããããå»åž«ã«ç¢ºèªããå°å
ãé«éœ¢è
ã§ã¯çšé調æŽãå¿
èŠã§ããã¢ã»ãã¢ãããã§ã³ïŒã«ãããŒã«ïŒã¯èè
žãåºè¡ãªã¹ã¯ãäœãã®ããã代æ¿ãšããŠæ€èšãããããšãå€ãã§ãããå¿
ãå»åž«ã«çžè«ããŠãã ããã
5. åžè²©è¬ vs. åŠæ¹è¬ã®æ¯èŒãšå
·äœçãªè£œååïŒå€æåºæºã瀺ãïŒ
ã©ã®è¬ãéžã¶ãã¯å¹æããªã¹ã¯ãã³ã¹ãã®ãã©ã³ã¹ã§ããããã§ã¯ä»£è¡šçãªè£œåã®ç¹åŸŽãæ¯èŒããŸãã
5-1. ãããœãã³SïŒç¬¬äžäžå
±ãã«ã¹ã±ã¢ïŒãšåŠæ¹ãããœãã³ã®éããå
·äœçã«
ãããœãã³Sã¯åžè²©ã®OTCè¬ã§ç·æ¥ã®çã¿ã«äœ¿ããããäžæ¹ãåŠæ¹ã®ãããœãã³é ã¯å»åž«ç®¡çã®äžã§çšéã調æŽã§ããå©ç¹ããããŸããåŠæ¹è¬ã¯å»åž«ãæç
ã䜵çšè¬ã確èªããŠããããããå®å
šé¢ãé«ãã§ãã
5-2. ã«ãããŒã«ïŒã¢ã»ãã¢ãããã§ã³ïŒãšã®äœ¿ãåãïŒèã«åªããã»åºè¡ãªã¹ã¯äœãïŒ
ã¢ã»ãã¢ãããã§ã³ã¯NSAIDsãšç°ãªãæççäœçšã匱ãã§ãããèãžã®åºæ¿ãå°ãªãåºè¡ãªã¹ã¯ãäœãã®ã§ãèè
žã匱ã人ãæååºè¬ã飲ãã§ãã人ã«ã¯éžã°ããããšãå€ãã§ãã
5-3. ããã¡ãªã³ãã€ããããã§ã³ãªã©ä»ã®åžè²©é®çè¬ãšã®æ¯èŒ
ã€ããããã§ã³ãNSAIDsã§ãããççãšçã¿ã«å¹æããããŸããããã¡ãªã³ã«ã¯ã¢ã¹ããªã³ç³»ã®è£œå€ããããåºè¡ãªã¹ã¯ãèè
žçç¶ãåºãããç¹ã«æ³šæãå¿
èŠã§ããåæåã®éããçè§£ããŠéžã³ãŸãããã
5-4. é®çå€çšå€ïŒãããœãã³ããŒãçïŒã®äœ¿ãéãšéç
ãããœãã³ããŒããªã©ã®å€çšNSAIDsã¯å±æçãªçã¿ã«äŸ¿å©ã§ãããç®èã®åºæ¿ãæ¥è§Šç®èçãåŒãèµ·ããå¯èœæ§ããããŸããã¬ãŒã¶ãŒç
§å°çŽåŸã®ç®èã¯ææãªã®ã§ãå€çšå€ã®äœ¿çšã¯ã¯ãªããã¯ã®æç€ºãä»°ãã§ãã ããã
5-5. è¬ãéžã¶ãšãã®ãã§ãã¯ãªã¹ãïŒã¢ã¬ã«ã®ãŒæŽãå
æè¬ã®æç¡ãæç
ïŒ
è¬ãéžã¶éã¯å¿
ã以äžã確èªããŸãããïŒ
- éå»ã«NSAIDsã§ã¢ã¬ã«ã®ãŒããã£ãã
- æååºè¬ãéå§è¬ãªã©åžžçšè¬ãããã
- èæœ°çãè
çŸæ£ã®æ¢åŸãããã
- åŠåš ã»æä¹³ã®å¯èœæ§ãããã
6. ã¯ãªããã¯å¥ã®å®éã®å¯Ÿå¿ãšå£ã³ãïŒå
·äœåã§æ¯èŒïŒ
äž»èŠã¯ãªããã¯ã®äžè¬çãªå¯Ÿå¿åŸåããŸãšããŸããå®éã®å¯Ÿå¿ã¯é¢ã«ãã£ãŠç°ãªããããäºå確èªãéèŠã§ãã
6-1. æ¹åçŸå®¹ã¯ãªããã¯ïŒSBCïŒïŒé®çè¬ã®åŠæ¹æ¹éãšéº»é
察å¿ãå£ã³ããŸãšã
æ¹åçŸå®¹ã¯ãªããã¯ã§ã¯éšäœãæœè¡å
容ã«å¿ããŠéº»é
ã¯ãªãŒã ãç¬æ°éº»é
ãå¿
èŠã«å¿ãåŠæ¹é®çè¬ãæ¡å
ããããšãå€ãã§ããå£ã³ãã§ã¯ãã¹ã¿ããã®èª¬æãæåãããVIOã¯ç¬æ°ã麻é
ãå§ããããããšãã声ãå€ãèŠãããŸãã
6-2. ã¬ãžãŒãã¯ãªããã¯ïŒæœè¡åŸã®é®çæå°ã麻é
ã¯ãªãŒã ãç¬æ°ã®æç¡
ã¬ãžãŒãã¯ãªããã¯ã¯å¥³æ§å°çšã»èãžã®é
æ
®ãéèŠããé¢ãå€ãã麻é
ã¯ãªãŒã ã®äœ¿çšãè¡åŸã®å€çšã±ã¢æå°ããã£ããããŠãããšããè©å€ããããŸããçã¿ãæããããã®äºåçžè«ãåãä»ããã±ãŒã¹ãå€ãã§ãã
6-3. ãªãŒã¯ãªããã¯ïŒåŠæ¹è¬ã»éº»é
ã®éžæè¢ãææèãžã®é
æ
®äºäŸ
ãªãŒã¯ãªããã¯ã¯ææèã®æ£è
ã«å¯ŸããŠãè€æ°ã®éº»é
ãªãã·ã§ã³ãçšæããŠããããšãå€ããåŠæ¹è¬ã®å€æãå»åž«ãåå¥ã«è¡ããšãããŠããŸããå£ã³ãã§ã¯ãææèã§ãåããããããçã¿ã®çžè«ã«èŠªèº«ã«çããŠãããããšã®å£°ãç®ç«ã¡ãŸãã
6-4. ãã¬ã€ã¢ã¯ãªããã¯ïŒçã¿å¯ŸçïŒä¿å·ã»éº»é
ïŒãã¹ã¿ããã®æ¡å
äŸ
ãã¬ã€ã¢ã¯ãªããã¯ã¯èç±åŒã®æ©åšã䜿ãé¢ãå€ããæœè¡äžã®å·åŽãšéº»é
ã¯ãªãŒã ã®äœµçšãæ¡å
ããããšãäžè¬çã§ããã¹ã¿ããæè²ãè¡ãå±ããŠãããšããè©å€ãå€ãäžæ¹ãæœè¡äºçŽã®æ··éããããšã®ææãäžéšã«ãããŸãã
6-5. ã¡ã³ãºãªãŒïŒç·æ§ã®ãã²è±æ¯ã§ã®é®çå®åãšãããœãã³ã®æ±ã
ã¡ã³ãºãªãŒã¯ç·æ§åãã®å¯Ÿå¿ã«æ
£ããŠããããã²è±æ¯ã®çã¿å¯ŸçãšããŠç¬æ°ãã¯ãªãŒã 麻é
ãææ¡ããããšãå€ãã§ãããããœãã³ã®åŠæ¹ã«ã€ããŠãåå¥ã®å¥åº·ç¶æ
ã確èªããŠãã倿ããã±ãŒã¹ãå€ãå ±åãããŠããŸãã
7. 代æ¿ã®é®çã»ã±ã¢æ¹æ³ïŒè¬ä»¥å€ã§çã¿ããããããå
·äœçïŒ
è¬ä»¥å€ã«ã广çãªæ¹æ³ãããã€ããããŸããããããçµã¿åããããšé®ç广ãäžãããŸãã
7-1. å·åŽïŒä¿å·å€ïŒã®æ£ããäœ¿ãæ¹ãšæ³šæç¹ïŒåå·é²æ¢ïŒ
æœè¡çŽåŸã®å·åŽã¯æå¹ã§ãããæ°·ãçŽã«åœãŠããšåå·ã«ãªãå¯èœæ§ããããããã¿ãªã«ãæããå·åŽãžã§ã«ã䜿ããšå®å
šã§ãã10ïœ15åå·ãããŠã¯äŒããã®ç¹°ãè¿ããåºæ¬ã§ãã
7-2. 麻é
ã¯ãªãŒã ïŒEmlaãªã©ïŒã®å¹æãšäœ¿ãæ¹ã»è³Œå
¥æ¹æ³
EmlaïŒãšã ã©ïŒãªã©ã®å±æéº»é
ã¯ãªãŒã ã¯äºåã«å¡åžããŠäžå®æéïŒè£œåã«ããïŒåŸ
ã€ããšã§ç®èã®ç¥èŠãéãããŸããã¯ãªããã¯ã§åŠæ¹ã»æ¡å
ãããå Žåãå€ãã§ãããåžè²©ã®é¡äŒŒè£œåããããŸããäœ¿çšæ¹æ³ã¯å¿
ãæç€ºã«åŸã£ãŠãã ããã
7-3. ã¯ãªããã¯ã§åãããã麻é
ãªãã·ã§ã³ïŒå±æéº»é
ã»ç¬æ°éº»é
ïŒ
å±ææ³šå°ã«ãã麻é
ã¯åŒ·åã§ããæ³šå°èªäœã®çã¿ãããå Žåããããç¬æ°éº»é
ã¯ãªã©ãã¯ã¹ããŠçã¿ãåããã广ãé«ãã§ããã©ã¡ããã¯ãªããã¯ã«ãã£ãŠæäŸã®æç¡ãæéãç°ãªããŸãã
7-4. ã¢ãã¿ãŒã±ã¢ã§ççãæããå€çšå€ïŒãã«ãã€ããã¢ãºããŒã«ãªã©ïŒãšäœµçšæ³šæ
ãã«ãã€ããã¢ãºããŒã«ã¯è¡åŸã®ä¿æ¹¿ãççç·©åã«äœ¿ãããããšããããŸãããNSAIDsãšã®äœµçšã§åé¡ãèµ·ããããšã¯å°ãªããã®ã®ãç®èç¶æ
ã«ãã£ãŠã¯å»åž«ã®æç€ºã«åŸãã¹ãã§ãã
7-5. ãªã©ãã¯ã¹æ³ã»åŒåžæ³ã»åœæ¥ã®å·¥å€«ïŒæœè¡åã®é£äºã»ç¡ç ã»æè£
ïŒ
æ·±åŒåžããªã©ãã¯ã¹æ³ã¯çã¿ã®æãæ¹ã軜ãããŸããåœæ¥ã¯è»œãé£äºãåããååãªç¡ç ã確ä¿ããæœè¡ããããæè£
ïŒãã£ããããæïŒã§è¡ããšè² æ
ãæžããŸãã
8. ããããQ&AïŒèªè
ãæ€çŽ¢ããããå
·äœåçïŒ
æ€çŽ¢ã§ããåºãçåãQ&A圢åŒã§çãåãããããçããŸããåå¥ã®æçµå€æã¯å¿
ãå»åž«ã«çžè«ããŠãã ããã
8-1. QïŒæœè¡åã«ãããœãã³ã飲ãã§ããè¡ã£ãŠã倧äžå€«ïŒ
AïŒã¯ãªããã¯ã®æ¹éã«ãããŸããäºé²å
æãèš±å¯ãããŠããå ŽåããããŸãããåºè¡ãªã¹ã¯ãæ¢åŸæŽãèæ
®ããŠã¯ãªããã¯ã«çžè«ããŸãããã
8-2. QïŒãããœãã³ã飲ãã§èµ€ã¿ãåŒããªããšãã¯ïŒ
AïŒèµ€ã¿ãç¶ãå Žåã¯ææã匷ãççã®å¯èœæ§ãããããããŸãã¯æœè¡ããã¯ãªããã¯ã«é£çµ¡ããŠèšºå¯ãåããŠãã ãããèªå·±å€æã§ç¶ç¶æçšããã®ã¯é¿ããŸãããã
8-3. QïŒæç
ã§è¡æ¶²ããµã©ãµã©ã«ããè¬ã飲ãã§ããããããœãã³ã¯OKïŒ
AïŒæååºè¬äœ¿çšäžã¯åºè¡ãªã¹ã¯å¢å€§ã®ãããååå»åž«ãšçžè«ã®äžã§å€æããŸããå Žåã«ãã£ãŠã¯NSAIDsãé¿ããŠã¢ã»ãã¢ãããã§ã³ã«åãæ¿ããæç€ºãåºãããšããããŸãã
8-4. QïŒåã©ããåŠåš äžã¯ã©ãããã°ããïŒ
AïŒåŠåš åŸæã¯NSAIDsã¯é¿ããã¹ãã§ããå°å
ãæä¹³äžãçšéã補å€éžæã«æ³šæãå¿
èŠã§ããå¿
ãæ
åœå»ã«çžè«ããŠãã ããã
8-5. QïŒæœè¡åŸã«åžè²©è¬ãšåŠæ¹è¬ã©ã¡ããã³ã¹ãè¯ãïŒ
AïŒã³ã¹ãã®è©äŸ¡ã¯å人差ããããŸããåžè²©è¬ã¯å®ãæè»œã§ãããåŠæ¹è¬ã¯å»åž«ã®ç®¡çäžã§ããå®å
šã«äœ¿ããå©ç¹ããããŸããæç
ãããã°åŠæ¹è¬ã®æ¹ãå®å¿ã§ãã
9. ç§ã®äœéšè«ïŒå®äœéšãå
·äœçã«ïŒ
ããã¯å®äœéšãæ£çŽã«æžããŸãããããŸã§å人ã®äœéšã§ãããäžè¬åã¯ã§ããŸãããåèã«ãªãã°å¬ããã§ãã
9-1. çäŸç޹ä»ïŒã¬ãžãŒãã¯ãªããã¯ã§ã¯ããšVIOãåãããšãã®çã¿ã¬ãã«ãšå¯ŸåŠïŒ2023幎6æïŒ
2023幎6æã«ã¬ãžãŒãã¯ãªããã¯ã§ã¯ããšVIOã®æœè¡ãåããŸãããã¯ãã¯å·åŽãšéº»é
ã¯ãªãŒã ã§èããããçšåºŠãVIOã¯ç¬æ°éº»é
ã䜵çšããŠããã¯ããšãã匷ãããããæœè¡åŸã¯ãããœãã³ïŒåžè²©ã®ãããœãã³SïŒã1åæçšããŠè
«ããšçã¿ãããªãåãããŸãããèã«å€§ããªãã©ãã«ã¯èµ·ããŸããã§ããããæœè¡åã«å»åž«ã«çžè«ããäžã§ã®æçšã§ãã
9-2. æ¹åçŸå®¹ã¯ãªããã¯ã§ã®å
šèº«æœè¡æã«ã¹ã¿ããããæ¡å
ãããé®çæ³ïŒ2022幎11æïŒ
2022幎11æã«æ¹åçŸå®¹ã¯ãªããã¯ã§äžåèº«ã®æœè¡ãåããéã¯ãæœè¡äžã®å·åŽãæœè¡åŸã«å¿
èŠãªãåŠæ¹é®çè¬ãåºãæšã®èª¬æãåããŸãããã¹ã¿ããã¯ãçã¿ã匷ããã°é æ
®ãªãèšã£ãŠãã ããããšç¹°ãè¿ããŠãããã®ã§å®å¿æããããŸããã
9-3. ç§ããããœãã³Sã䜿ã£ããšãã®å¹æã»å¯äœçšã®ææ³ïŒå
·äœçãªç¶æ³ïŒ
ãããœãã³Sãæœè¡åŸã«1åæçšãããšãããçŽ30ïœ60åã§çŒçãåãããŸãããèã®äžå¿«æã¯åºãŸããã§ããããå¥ã®åã§ã¯æçšåŸã«è»œãèããããæããããç¿åã¯é£åŸã«é£²ãããã«ããŸãããå人差ãããã®ã§ãèªåã®äœèª¿ãèŠãªãã䜿ãã®ã倧äºã§ãã
9-4. 倱æè«ïŒé£²ã¿åããã§ãã€ããšããäœéšãšãã®æèšïŒ2021幎4æïŒ
2021幎4æã«å¥ã®è¬ïŒåžè²©ã®é¢šéªè¬ïŒãšäžç·ã«é£²ãã§ããŸããã®ã¡ã«è¬å€åž«ãããäœµçšæ³šæãã®ææãåããŸããã幞ã倧äºã«ã¯è³ããŸããã§ããããäºåã«åžžçšè¬ããã®å Žã§é£²ãã§ããè¬ãç³åããªãã£ãããšãåçç¹ã§ãã以åŸã¯å¿
ãè¬ã®äžèЧãæåããŠããŸãã
9-5. ç·šééšã®ç·åèŠè§£ãšå人çãªããããïŒã©ããªäººã«ãããœãã³ãåããïŒ
å人çã«ã¯ãå¥åº·ã§èè
žãè
æ©èœã«åé¡ããªããã°ãè¡åŸã®çæçãªçã¿ã«ã¯ãããœãã³ã¯æå¹ãªéžæè¢ã ãšæããŸãããã ããæååºè¬ã䜿ã£ãŠãã人ãåŠåš äºå®ã®äººãæ¢åŸã«æžå¿µããã人ã¯ã«ãããŒã«ãªã©ä»£æ¿æ¡ãæ€èšãã¹ãã§ããã¯ãªããã¯ã§äºåã«çžè«ããæç€ºã«åŸãã®ãå®å
šã§ãã
10. ãŸãšãïŒå»çè±æ¯ãå®å
šã«åããããã®ãã§ãã¯ãªã¹ãïŒå®è·µã¢ã¯ã·ã§ã³ïŒ
æåŸã«ãæœè¡ååŸã«å®éã«ã§ãããã§ãã¯ãªã¹ãããŸãšããŸãããããæã£ãŠã¯ãªããã¯ã«è¡ãã°å®å¿æãé«ãŸããŸãã
10-1. æœè¡åã«ã¯ãªããã¯ã§å¿
ã確èªãã5é
ç®ïŒæ¢åŸæŽãåžžçšè¬ã麻é
ã®å¯åŠãªã©ïŒ
1. æ¢åŸæŽïŒè朰çãè
çŸæ£ãã¢ã¬ã«ã®ãŒïŒ
2. åžžçšè¬ïŒã¯ã«ãã¡ãªã³ãæè¡å°æ¿è¬ãéå§è¬çïŒ
3. åŠåš ã»æä¹³ã®å¯èœæ§
4. 䜿çšäºå®ã®éº»é
ïŒã¯ãªãŒã ãç¬æ°ã泚å°ïŒã®æç¡ãšè²»çš
5. æœè¡äžã»åŸã®é®çè¬ã®æ¹éïŒåžè²©è¬OKããåŠæ¹ãå¿
èŠãïŒ
10-2. åœæ¥æåãã¹ããã®ïŒåžžçšè¬ãä¿å·æãã«ããªãŒã®ãã軜é£ãªã©ïŒ
- åžžçšè¬ã®äžèЧïŒè¬ã®åç§°ãšçšéïŒ
- ä¿å·æïŒã¯ãªããã¯ã«ç¡ããã°æåïŒ
- 軜é£ïŒäœè¡ç³äºé²ã»äŒæ©åŸã®ãšãã«ã®ãŒïŒ
- é¡ãæœè¡éšäœãé ãããããã£ããããæ
10-3. æçšã®ç°¡åã¬ã€ãïŒãã€ãäœããã©ãã ãïŒâ»å»åž«ã®æç€ºãæåªå
- æœè¡åïŒã¯ãªããã¯æšå¥šãããã°æçšå¯ããã ãåºè¡ãªã¹ã¯ã®ãã人ã¯èŠçžè«ã
- æœè¡çŽåŸïŒçã¿ã匷ããã°æ©ãã«1åæçšïŒè£œå€ã®çšæ³ã«åŸãïŒã
- ç¶ç¶ïŒ2ïœ3æ¥ä»¥äžé£ç¶ããŠå¿
èŠãªãå»åž«ã«çžè«ããŠåŠæ¹ã§ç®¡çããŠãããã
10-4. ãã©ãã«çºçæã®å¯ŸåŠãããŒïŒèµ€ã¿ã»æ°Žã¶ããã»åºè¡æã®é£çµ¡å
ïŒ
- 軜床ã®èµ€ã¿ïŒå·åŽïŒé£çµ¡ïŒã¯ãªããã¯ã§æç€ºãåããïŒ
- æ°Žã¶ããã»è¿ãæ¿ããçã¿ïŒçŽã¡ã«ã¯ãªããã¯å蚺ïŒé»è©±ã§çç¶ãäŒããïŒ
- åºè¡ãæ¢ãŸããªãïŒå§è¿«æ¢è¡ãè¡ããæ¹åããªããã°ææ¥å蚺
10-5. æåŸã®ã¢ããã€ã¹ïŒèªåã«åãã¯ãªããã¯ãšã¹ã¿ããã®èŠã€ãæ¹
çã¿ãè¬ã®çžè«ã«äžå¯§ã«å¯Ÿå¿ããŠãããã¯ãªããã¯ã¯å®å¿æãéããŸããç¡æã«ãŠã³ã»ãªã³ã°ã§éº»é
ãé®çã®éžæè¢ãæœè¡å®çžŸãã¹ã¿ããã®å¯Ÿå¿ã確ãããèªåã®äžå®ãè§£æ¶ããŠããããšãããéžã³ãŸãããã
ãã®èšäºã®ãŸãšã
- ãããœãã³ïŒNSAIDsïŒã¯å€ãã®ã±ãŒã¹ã§å»çè±æ¯åŸã®ççæ§çŒçã«æå¹ããã ãæç
ãåžžçšè¬ãåŠåš ãªã©ã®æ¡ä»¶ã§ãªã¹ã¯ãå€ããã
- æœè¡åã«ã¯ãªããã¯ãšå¿
ãçžè«ããæç€ºã«åŸãããšãåžè²©ã®ãããœãã³Sã¯æè»œã ããåŠæ¹è¬ã®æ¹ãå®å
šç®¡çé¢ã§åªããå Žåãããã
- VIOããã²ãªã©çã¿ã匷ãéšäœã¯éº»é
ïŒã¯ãªãŒã ã»ç¬æ°ã»å±ææ³šå°ïŒã䜵çšããããšãå€ãã
- è¬ä»¥å€ã®æ¹æ³ïŒå·åŽã麻é
ã¯ãªãŒã ããªã©ãã¯ã¹æ³ïŒã广çã«äœµçšãããã
- ãã©ãã«ãããã°èªåã§å€æãããæœè¡ããã¯ãªããã¯ãå»åž«ã«ããçžè«ããããšã
åºå
žã»åè
ã»ç¬¬äžäžå
±ãã«ã¹ã±ã¢ïŒè£œåæ
å ±ïŒãããœãã³SïŒ
ã»å»ççšãããœãã³ïŒãããœãããã§ã³ïŒæ·»ä»ææž
ã»ã¢ã»ãã¢ãããã§ã³ïŒã«ãããŒã«ïŒè£œåæ
å ±
ãŽãªã©ã¯ãªããã¯ è±æ¯ ãªã³ã©ã€ã³èšºçã¯äœ¿ããïŒã¡ãªããã»æµãã»æ³šæç¹ã培åºè§£èª¬
ã»æ¥æ¬ç®èç§åŠäŒïŒå
ç·æ²»çïŒã¬ãŒã¶ãŒæ²»çã«é¢ããã¬ã€ãã©ã€ã³ç
ã»æ¹åçŸå®¹ã¯ãªããã¯ïŒå
¬åŒïŒæœè¡ã»éº»é
ã»ã¢ãã¿ãŒã±ã¢æ¡å
ã»ã¬ãžãŒãã¯ãªããã¯ïŒå
¬åŒïŒæœè¡ã»éº»é
ã«é¢ããæ¡å
ã»ãªãŒã¯ãªããã¯ïŒå
¬åŒïŒè±æ¯ã»éº»é
察å¿ã®æ¡å
ã»ãã¬ã€ã¢ã¯ãªããã¯ïŒå
¬åŒïŒæœè¡ãšçã¿å¯Ÿçã®æ¡å
ã»ã¡ã³ãºãªãŒïŒå
¬åŒïŒç·æ§åãè±æ¯ãšéº»é
察å¿ã®æ¡å
ã»äžè¬åãå»è¬åå®å
šäœ¿çšæ
å ±ïŒåçåŽåçé¢é£è³æïŒ
ïŒäžèšã¯æ¬æäžã®äž»åŒµãè£ä»ããåèè³æã§ããå
·äœçãªäœ¿çšã蚺æã¯å¿
ãæ
åœå»åž«ã»è¬å€åž«ã«ãçžè«ãã ãããïŒ